Podiatrists across the U.S. are warning GLP-1 users about "Ozempic feet" - painful foot changes caused by rapid fat pad loss.
These shoes can make every single step a little less hostile to that irritated fascia.
Keenova Therapeutics plc, a leading US-focused branded therapeutics company, announced positive results from its phase 3 clinical trial of Xiaflex (collagenase clostridium histolyticum) for the ...
NBC Selected independently determines what we cover and recommend. When you click on or buy through our links, we earn a commission. Learn more. Mili Godio Updates Editor If you’re struggling with ...
Keenova Therapeutics is hoping to step into a new market with Xiaflex (collagenase clostridium histolyticum), after the drug netted a Phase III win in rare foot disease, plantar fibromatosis. To put ...
Treatment with CCH led to a clinically meaningful and statistically significant reduction in daily foot pain at week 12 compared with placebo. Topline data were announced from a phase 3 trial ...
Keenova Therapeutics plc announced today positive results from its Phase 3 clinical trial of XIAFLEX® (collagenase clostridium ...
The pivotal trial met the primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in pain versus placebo, as measured by the Average Daily Pain Intensity on ...